{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T13:27:56Z","timestamp":1768915676710,"version":"3.49.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Scientific Research Foundation for talents of Wenzhou Medical University","award":["QTJ18024"],"award-info":[{"award-number":["QTJ18024"]}]},{"name":"Scientific Research Foundation for talents of Wenzhou Medical University","award":["QTJ18023"],"award-info":[{"award-number":["QTJ18023"]}]},{"name":"Scientific Research Foundation for talents of Wenzhou Medical University","award":["QTJ18029"],"award-info":[{"award-number":["QTJ18029"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["61973240"],"award-info":[{"award-number":["61973240"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>An accurate prognosis assessment for cancer patients could aid in guiding clinical decision-making. Reliance on traditional clinical features alone in a complex clinical environment is challenging and unsatisfactory in the era of precision medicine; thus, reliable prognostic biomarkers are urgently required to improve a patient staging system. In this study, we proposed a patient-level computational framework from mechanistic and translational perspectives to establish a personalized prognostic signature (named PLPPS) in high-grade serous ovarian carcinoma (HGSOC). The PLPPS composed of 68 immune genes achieved accurate prognostic risk stratification for 1190 patients in the meta-training cohort and was rigorously validated in multiple cross-platform independent cohorts comprising 792 HGSOC patients. Furthermore, the PLPPS was shown to be the better prognostic factor compared with clinical parameters in the univariate analysis and retained a significant independent association with prognosis after adjusting for clinical parameters in the multivariate analysis. In benchmark comparisons, the performance of PLPPS (hazard ratio (HR), 1.371; concordance index (C-index), 0.604 and area under the curve (AUC), 0.637) is comparable to or better than other published gene signatures (HR, 0.972 to 1.340; C-index, 0.495 to 0.592 and AUC, 0.48\u20130.624). With further validation in prospective clinical trials, we hope that the PLPPS might become a promising genomic tool to guide personalized management and decision-making of HGSOC in clinical practice.<\/jats:p>","DOI":"10.1093\/bib\/bbaa069","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T11:15:21Z","timestamp":1585826121000},"source":"Crossref","is-referenced-by-count":16,"title":["Mechanistically derived patient-level framework for precision medicine identifies a personalized immune prognostic signature in high-grade serous ovarian cancer"],"prefix":"10.1093","volume":"22","author":[{"given":"Hengqiang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congcong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"2021052109425718400_ref1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2021052109425718400_ref2","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2021052109425718400_ref3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ygyno.2016.03.010","article-title":"Characteristics of 10-year survivors of high-grade serous ovarian carcinoma","volume":"141","author":"Dao","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021052109425718400_ref4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature"},{"key":"2021052109425718400_ref5","volume-title":"Omics Data Integration Analysis in High Grade Serous Ovarian Cancer: Results from Three Studies","author":"Natanzon","year":"2017"},{"key":"2021052109425718400_ref6","first-page":"1","article-title":"Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long-and short-term survivors","volume-title":"Genome Med","author":"Yang","year":"2018"},{"key":"2021052109425718400_ref7","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.7150\/jca.25587","article-title":"Development of a novel autophagy-related prognostic signature for serous ovarian cancer","volume":"9","author":"An","year":"2018","journal-title":"J Cancer"},{"key":"2021052109425718400_ref8","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1158\/0008-5472.CAN-07-6595","article-title":"A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer","volume":"68","author":"Bonome","year":"2008","journal-title":"Cancer Res"},{"key":"2021052109425718400_ref9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/path.2547","article-title":"A prognostic gene expression index in ovarian cancer - validation across different independent data sets","volume":"218","author":"Denkert","year":"2009","journal-title":"J Pathol"},{"key":"2021052109425718400_ref10","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-11-2725","article-title":"High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway","volume":"18","author":"Yoshihara","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021052109425718400_ref11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2016.01.026","article-title":"Gene-expression signatures in ovarian cancer: promise and challenges for patient stratification","volume":"141","author":"Konecny","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021052109425718400_ref12","first-page":"670","article-title":"A DNA repair pathway\u2013focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy","volume-title":"J Natl Cancer Inst","author":"Kang","year":"2012"},{"key":"2021052109425718400_ref13","first-page":"1159","article-title":"Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer","volume-title":"J Mol Med (Berl)","author":"Lu","year":"2014"},{"key":"2021052109425718400_ref14","first-page":"1203","article-title":"Effects of hub genes on the clinicopathological and prognostic features of lung adenocarcinoma","volume":"19","author":"Yu","year":"2020","journal-title":"Oncol Lett"},{"key":"2021052109425718400_ref15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3389\/fgene.2019.01408","article-title":"Identification of prognostic genes in Leiomyosarcoma by gene co-expression network analysis","volume":"10","author":"Yang","year":"2019","journal-title":"Front Genet"},{"key":"2021052109425718400_ref16","doi-asserted-by":"crossref","first-page":"3518378","DOI":"10.1155\/2019\/3518378","article-title":"Identification of key genes and prognostic value analysis in hepatocellular carcinoma by integrated bioinformatics analysis","volume":"2019","author":"Wang","year":"2019","journal-title":"Int J Genomics"},{"key":"2021052109425718400_ref17","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbz078","article-title":"HiFreSP: a novel high-frequency sub-pathway mining approach to identify robust prognostic gene signatures, brief bioinform","author":"Li","year":"2019"},{"key":"2021052109425718400_ref18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nrg2825","article-title":"Tackling the widespread and critical impact of batch effects in high-throughput data","volume":"11","author":"Leek","year":"2010","journal-title":"Nat Rev Genet"},{"key":"2021052109425718400_ref19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/bib\/bbv064","article-title":"Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer","volume":"17","author":"Qi","year":"2016","journal-title":"Brief Bioinform"},{"key":"2021052109425718400_ref20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41419-019-1874-9","article-title":"Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis"},{"key":"2021052109425718400_ref21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/bib\/bbu049","article-title":"Measures for the degree of overlap of gene signatures and applications to TCGA","volume":"16","author":"Shi","year":"2015","journal-title":"Brief Bioinform"},{"key":"2021052109425718400_ref22","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/bioinformatics\/btq064","article-title":"GOSemSim: an R package for measuring semantic similarity among GO terms and gene products","volume":"26","author":"Yu","year":"2010","journal-title":"Bioinformatics"},{"key":"2021052109425718400_ref23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"2021052109425718400_ref24","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021052109425718400_ref25","first-page":"5270","article-title":"Integrative analysis from multi-Centre studies identifies a function-derived personalized multi-gene signature of outcome in colorectal cancer","volume-title":"J Cell Mol Med","author":"Sun","year":"2019"},{"key":"2021052109425718400_ref26","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju049","article-title":"Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer","volume":"106","author":"Waldron","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021052109425718400_ref27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.323.7306.224","article-title":"Systematic reviews of evaluations of prognostic variables","volume":"323","author":"Altman","year":"2001","journal-title":"BMJ"},{"key":"2021052109425718400_ref28","first-page":"1529","article-title":"Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non\u2013small cell lung cancer","volume-title":"JAMA Oncol","author":"Li","year":"2017"},{"key":"2021052109425718400_ref29","first-page":"1016","article-title":"Revisiting the hallmarks of cancer","volume":"7","author":"Fouad","year":"2017","journal-title":"Am J Cancer Res"},{"key":"2021052109425718400_ref30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/1479-5876-11-147","article-title":"Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer","volume":"11","author":"Lavoue","year":"2013","journal-title":"J Transl Med"}],"container-title":["Briefings in Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/3\/bbaa069\/37963488\/bbaa069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bib\/article-pdf\/22\/3\/bbaa069\/37963488\/bbaa069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T09:43:13Z","timestamp":1621590193000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bib\/article\/doi\/10.1093\/bib\/bbaa069\/5840066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bib\/bbaa069","relation":{},"ISSN":["1467-5463","1477-4054"],"issn-type":[{"value":"1467-5463","type":"print"},{"value":"1477-4054","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5]]},"published":{"date-parts":[[2020,5,20]]},"article-number":"bbaa069"}}